RxDoctor Payments Data

Michael Carroll, MD

Family Medicine · Traverse City, MINPI 1346338324

Payments from drug & device makers

$17,573in general payments, 2019–2025

Across 1,140 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • GSK$1K
  • plus $9K from 49 others

What the payments were for

  • Food & beverage$17,532100%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,573 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$170,621
Medicare patients
465
Services billed
2,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$144,998
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$97,698
MounjaroTirzepatide68$89,422
JardianceEmpagliflozin60$78,160
TrulicityDulaglutide37$56,478
FarxigaDapagliflozin Propanediol29$43,149
OzempicSemaglutide22$39,856
XareltoRivaroxaban28$31,626
RexultiBrexpiprazole14$28,357
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$25,045
Soliqua 100-33Insulin Glargine/Lixisenatide19$19,036
VraylarCariprazine Hcl12$16,321
Atorvastatin Calcium421$7,251
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide118$7,018
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$5,905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,260$145,900105 claims
PfizerEliquis$818$144,998112 claims
GSKTrelegy Ellipta$1,174$97,69891 claims
Boehringer IngelheimJardiance$401$78,16060 claims
AstraZenecaFarxiga$1,312$43,14929 claims
Novo NordiskOzempic$1,478$39,85622 claims
Johnson & JohnsonXarelto$293$31,62628 claims
Otsuka America Pharmaceutical, Inc.Rexulti$660$28,35714 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$398$19,03619 claims
AbbVieVraylar, Synthroid$1,963$18,84240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Traverse City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →